• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利：CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法，用中文像聊天一样搜索，搜遍4000万医学文献。AI智能推荐，让科研检索更轻松。

立即免费搜索

文件翻译

保留排版，准确专业，支持PDF/Word/PPT等文件格式，支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述，25分钟生成高质量综述，智能提取关键信息，辅助科研写作。

立即免费体验

Adverse events reported with BPaL and BPaLM regimens in drug-resistant tuberculosis.

作者信息

Sridharan Kannan, Sivaramakrishnan Gowri

机构信息

Department of Pharmacology & Therapeutics, College of Medicine & Health Sciences, Arabian Gulf University, Manama, Bahrain.

Bahrain Defence Force Royal Medical Services, Riffa, Bahrain.

出版信息

J Clin Tuberc Other Mycobact Dis. 2025 May 6;40:100533. doi: 10.1016/j.jctube.2025.100533. eCollection 2025 Aug.

DOI:10.1016/j.jctube.2025.100533
PMID:40469260
原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC12136811/
Abstract
摘要

相似文献

1
Adverse events reported with BPaL and BPaLM regimens in drug-resistant tuberculosis.在耐多药结核病中使用BPaL和BPaLM方案报告的不良事件。
J Clin Tuberc Other Mycobact Dis. 2025 May 6;40:100533. doi: 10.1016/j.jctube.2025.100533. eCollection 2025 Aug.
2
Experience of piloting BPaLM/BPaL for DR-TB care at selected sites in Pakistan.在巴基斯坦选定地点试点将BPaLM/BPaL用于耐多药结核病治疗的经验。
IJTLD Open. 2024 Nov 1;1(11):508-515. doi: 10.5588/ijtldopen.24.0369. eCollection 2024 Nov.
3
Short oral regimens for pulmonary rifampicin-resistant tuberculosis (TB-PRACTECAL): an open-label, randomised, controlled, phase 2B-3, multi-arm, multicentre, non-inferiority trial.简短口服方案治疗肺部利福平耐药结核病（TB-PRACTECAL）：一项开放标签、随机、对照、2B-3 期、多臂、多中心、非劣效性试验。
Lancet Respir Med. 2024 Feb;12(2):117-128. doi: 10.1016/S2213-2600(23)00389-2. Epub 2023 Nov 16.
4
Safety and Effectiveness of BPaL-Based Regimens to Treat Multidrug-Resistant TB: First Experience of an Italian Tuberculosis Referral Hospital.基于BPaL方案治疗耐多药结核病的安全性和有效性：一家意大利结核病转诊医院的首次经验。
Antibiotics (Basel). 2024 Dec 25;14(1):7. doi: 10.3390/antibiotics14010007.
5
Savings from the introduction of BPaL and BPaLM regimens at the country level.在国家层面引入BPaL和BPaLM治疗方案所带来的节省。
IJTLD Open. 2024 Jul 1;1(7):314-319. doi: 10.5588/ijtldopen.24.0213. eCollection 2024 Jul.
6
Impact and cost-effectiveness of the 6-month BPaLM regimen for rifampicin-resistant tuberculosis in Moldova: A mathematical modeling analysis.摩尔多瓦利福平耐药结核病 6 个月 BPaLM 方案的影响和成本效益：一项数学建模分析。
PLoS Med. 2024 May 3;21(5):e1004401. doi: 10.1371/journal.pmed.1004401. eCollection 2024 May.
7
The Effectiveness and Safety of Bedaquiline, Pretomanid, and Linezolid (BPaL)-Based Regimens for Rifampicin-Resistant Tuberculosis in Non-Trial Settings-A Prospective Cohort Study in Belarus and Uzbekistan.基于贝达喹啉、普瑞玛尼和利奈唑胺（BPaL）的方案在非试验环境中治疗耐利福平结核病的有效性和安全性——白俄罗斯和乌兹别克斯坦的一项前瞻性队列研究
Clin Infect Dis. 2025 Feb 18. doi: 10.1093/cid/ciaf035.
8
Experiences in the introduction of bedaquiline pretomanid linezolid for drug-resistant tuberculosis in Kyrgyzstan.吉尔吉斯斯坦引入贝达喹啉、普瑞玛尼和利奈唑胺治疗耐多药结核病的经验。
J Clin Tuberc Other Mycobact Dis. 2024 Jul 26;36:100472. doi: 10.1016/j.jctube.2024.100472. eCollection 2024 Aug.
9
The Safety and Tolerability of Linezolid in Novel Short-Course Regimens Containing Bedaquiline, Pretomanid, and Linezolid to Treat Rifampicin-Resistant Tuberculosis: An Individual Patient Data Meta-analysis.贝达喹啉、普托马尼和利奈唑胺新短程方案治疗利福平耐药结核病的安全性和耐受性：一项个体患者数据荟萃分析。
Clin Infect Dis. 2024 Mar 20;78(3):730-741. doi: 10.1093/cid/ciad653.
10
Availability of drugs and resistance testing for bedaquiline, pretomanid, linezolid, and moxifloxacin (BPaL(M)) regimen for rifampicin-resistant tuberculosis in Europe.在欧洲，利福平耐药结核病的贝达喹啉、普托马尼德、利奈唑胺和莫西沙星（BPaL（M））方案的药物供应和耐药检测情况。
Clin Microbiol Infect. 2024 Sep;30(9):1197.e1-1197.e4. doi: 10.1016/j.cmi.2024.03.009. Epub 2024 Mar 13.

引用本文的文献

1
Treatment outcomes among patients with drug-resistant tuberculosis managed with BPaL/BPaLM regimen in the Southeast Zone of Nigeria.
Pan Afr Med J. 2025 Aug 5;51:86. doi: 10.11604/pamj.2025.51.86.48418. eCollection 2025.

本文引用的文献

1
Experiences in the introduction of bedaquiline pretomanid linezolid for drug-resistant tuberculosis in Kyrgyzstan.吉尔吉斯斯坦引入贝达喹啉、普瑞玛尼和利奈唑胺治疗耐多药结核病的经验。
J Clin Tuberc Other Mycobact Dis. 2024 Jul 26;36:100472. doi: 10.1016/j.jctube.2024.100472. eCollection 2024 Aug.
2
Pharmacovigilance: a science or fielding emergencies?药物警戒：一门科学还是应对突发事件的领域？
Stat Med. 2000 Dec 15;19(23):3199-209. doi: 10.1002/1097-0258(20001215)19:23<3199::aid-sim621>3.0.co;2-q.